Speaker: Ari Hakimian, DO , Hematology/Oncology Fellow, Advocate Lutheran General Hospital
Journal Articles:
- CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease | NEJM
2. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors | NEJM
Session date:
11/16/2023 - 8:00am to 9:00am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 1.00 AttendanceAttendance Credit